Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for Bradmer Pharmaceuticals in a research report issued on Wednesday, May 14th. HC Wainwright analyst M. Colonnese now expects that the company will earn ($1.20) per share for the quarter, down from their previous estimate of ($0.76). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS and FY2025 earnings at ($1.41) EPS.
GLX has been the subject of several other research reports. Benchmark raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 31st. Cantor Fitzgerald raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. Finally, BTIG Research raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 14th.
Bradmer Pharmaceuticals Stock Performance
Recommended Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- About the Markup Calculator
- Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?
- What is a Dividend King?
- 3 Small-Cap Stocks With Room to Run Despite Tariff Headwinds
- How to Use High Beta Stocks to Maximize Your Investing Profits
- CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
